Genase Therapeutics develops GTX-196, a small molecule inhibitor targeting the DHODH enzyme for cancer treatment, aiming to exploit metabolic vulnerabilities in oncogene addicted cancers
Genase Therapeutics develops GTX-196, a small molecule inhibitor targeting the DHODH enzyme for cancer treatment, aiming to exploit metabolic vulnerabilities in oncogene addicted cancers.